CVS Health Corp (NYSE:CVS) shares were weak in pre-market trading after the drugstores operator cuts its full-year earnings guidance despite reporting second-quarter earnings and revenue ahead of estimates.
The NYSE-listed group saw its net income for the quarter to the end of June rise to US$1.01bn, up from US$924.0mln a year earlier, giving adjusted earnings per share (EPS) of US$1.33.
The firm's revenue for the quarter increased by 4.5% to US$45.7bn, up from US$43.7bn in the corresponding quarter last year.
But looking ahead, CVS revised its full year EPS guidance to US$4.92 to US$5.02, from US$5.02 to US$5.18 previously. It also revised its full year adjusted EPS guidance to US$5.83 to US$5.93, from US$5.77 to US$5.93.
After initially pointing higher, half an hour ahead of the New York restart, CVS shares were 2% lower at US$77.50